RecruitingPhase 2NCT06376669

Stereotactic Body Proton Therapy for Treatment of Primary Renal Cell Carcinoma

Prospective Phase II Study of Stereotactic Body Proton Therapy for Treatment of PrimAry Renal Cell Carcinoma (SPARE)

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Enrollment

20 participants

Start Date

Feb 25, 2025

Study Type

INTERVENTIONAL

Conditions

Renal Cell Carcinoma

Summary

This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.

Eligibility

Min Age: 18 Years

Inclusion Criteria5

Age ≥ 18 years
Biopsy proven renal cell carcinoma.
No clinical or radiographic evidence of metastatic disease.
Not a candidate for surgical treatment or local ablative procedures.
Subjects are able to undergo either an MRI or administration of contrast agent for CT.

Exclusion Criteria3

Prior history of radiation treatment with overlapping fields.
Patients with proven metastatic disease.
Female subjects who are pregnant or planning to become pregnant during the treatment.

Interested in this trial?

Get notified about updates and connect with the research team.